Ciprofloxacin/Celecoxib
AssetAlso Fixed dose combination Ciprofloxacin/Celecoxib
Fixed-dose combination of ciprofloxacin and celecoxib targeting neuroinflammation and RNA processing in neurodegeneration.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Inflammation
- 2
- Indications
- 382
- Trials
- 1
- Developer
Indications
2ALS
Phase 2, Completed, NCT04165850, clinicaltrials.gov, 7 Oct 2026
Amyotrophic lateral sclerosis
Phase 2, Completed, NCT04165850, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Trials382
- Evidence for its targets3
- Competitors12
- Aging relevance2
Every asset’s record: target, stage, trials and the evidence behind it.